IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors.

Abstract

OBJECTIVES:

To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and explore mechanistic links between diseased tissue pathology and clinical outcomes.

METHODS:

Twenty-seven active PsA patients were enrolled in an observational/open-label study and underwent biopsies of synovium and paired lesional/non-lesional skin before starting anti-tumour necrosis factor (TNF) (if biologic-naïve) or ustekinumab (if anti-TNF inadequate responders). Molecular analysis of 80-inflammation-related genes and protein levels for interleukin (IL)-23p40/IL-23p19/IL-23R were assessed by real-time-PCR and immunohistochemistry, respectively.

RESULTS:

At baseline, all patients had persistent active disease as per inclusion criteria. At primary end-point (16-weeks post-treatment), skin responses favoured ustekinumab, while joint responses favoured anti-TNF therapies. Principal component analysis revealed distinct clustering of synovial tissue gene expression away from the matched skin. While IL12B, IL23A and IL23R were homogeneously expressed in lesional skin, their expression was extremely heterogeneous in paired synovial tissues. Here, IL-23 transcriptomic/protein expression was strongly linked to patients with high-grade synovitis who, however, were not distinguishable by conventional clinimetric measures.

CONCLUSIONS:

PsA synovial tissue shows a heterogeneous IL-23 axis profile when compared with matched skin. Synovial molecular pathology may help to identify among clinically indistinguishable patients those with a greater probability of responding to IL-23 inhibitors.

• Authors: Alessandra Nerviani, Marie-Astrid Boutet, Wang Sin Gina Tan, Katriona Goldmann, Nirupam Purkayastha, Tamas Ajtos Lajtos, Rebecca Hands, Myles Lewis, Stephen Kelly, Costantino Pitzalis
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 80 Issue 5 Pg. 591-597 (05 2021) ISSN: 1468-2060 [Electronic] England
• PMID: 33243781 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Chemical References

• Antirheumatic Agents
• Interleukin-17
• Interleukin-23
• Tumor Necrosis Factor Inhibitors
• Ustekinumab

Topics

• Adult
• Antirheumatic Agents (therapeutic use)
• Arthritis, Psoriatic (drug therapy, genetics, pathology)
• Female
• Gene Expression Profiling
• Humans
• Interleukin-17 (antagonists & inhibitors)
• Interleukin-23 (antagonists & inhibitors, metabolism)
• Male
• Middle Aged
• Principal Component Analysis
• Skin (metabolism)
• Synovial Membrane (metabolism)
• Synovitis (genetics)
• Treatment Outcome
• Tumor Necrosis Factor Inhibitors (therapeutic use)
• Ustekinumab (therapeutic use)